These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

454 related items for PubMed ID: 16914578

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.
    Cloughesy TF, Wen PY, Robins HI, Chang SM, Groves MD, Fink KL, Junck L, Schiff D, Abrey L, Gilbert MR, Lieberman F, Kuhn J, DeAngelis LM, Mehta M, Raizer JJ, Yung WK, Aldape K, Wright J, Lamborn KR, Prados MD.
    J Clin Oncol; 2006 Aug 01; 24(22):3651-6. PubMed ID: 16877733
    [Abstract] [Full Text] [Related]

  • 4. Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment.
    Razis E, Selviaridis P, Labropoulos S, Norris JL, Zhu MJ, Song DD, Kalebic T, Torrens M, Kalogera-Fountzila A, Karkavelas G, Karanastasi S, Fletcher JA, Fountzilas G.
    Clin Cancer Res; 2009 Oct 01; 15(19):6258-66. PubMed ID: 19789313
    [Abstract] [Full Text] [Related]

  • 5. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
    Walker AR, Komrokji RS, Ifthikharuddin J, Messina P, Mulford D, Becker M, Friedberg J, Oliva J, Phillips G, Liesveld JL, Abboud C.
    Leuk Res; 2008 Dec 01; 32(12):1830-6. PubMed ID: 18571721
    [Abstract] [Full Text] [Related]

  • 6. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults.
    Menon-Andersen D, Mondick JT, Jayaraman B, Thompson PA, Blaney SM, Bernstein M, Bond M, Champagne M, Fossler MJ, Barrett JS.
    Cancer Chemother Pharmacol; 2009 Jan 01; 63(2):229-38. PubMed ID: 18398615
    [Abstract] [Full Text] [Related]

  • 7. Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid.
    Yung WK, Kyritsis AP, Gleason MJ, Levin VA.
    Clin Cancer Res; 1996 Dec 01; 2(12):1931-5. PubMed ID: 9816151
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers.
    Coleman RL, Broaddus RR, Bodurka DC, Wolf JK, Burke TW, Kavanagh JJ, Levenback CF, Gershenson DM.
    Gynecol Oncol; 2006 Apr 01; 101(1):126-31. PubMed ID: 16271384
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Imatinib mesylate in the treatment of advanced gastrointestinal stromal tumors].
    Wan DS, Wu XJ, Pan ZZ, Zhou ZW, Chen G, Li LR, Lu ZH, Ding PR.
    Zhonghua Yi Xue Za Zhi; 2006 Nov 21; 86(43):3064-7. PubMed ID: 17288838
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.
    Dagher R, Cohen M, Williams G, Rothmann M, Gobburu J, Robbie G, Rahman A, Chen G, Staten A, Griebel D, Pazdur R.
    Clin Cancer Res; 2002 Oct 21; 8(10):3034-8. PubMed ID: 12374669
    [Abstract] [Full Text] [Related]

  • 18. A Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours.
    Baruchel S, Sharp JR, Bartels U, Hukin J, Odame I, Portwine C, Strother D, Fryer C, Halton J, Egorin MJ, Reis RM, Martinho O, Stempak D, Hawkins C, Gammon J, Bouffet E.
    Eur J Cancer; 2009 Sep 21; 45(13):2352-9. PubMed ID: 19505817
    [Abstract] [Full Text] [Related]

  • 19. A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer.
    Modi S, Seidman AD, Dickler M, Moasser M, D'Andrea G, Moynahan ME, Menell J, Panageas KS, Tan LK, Norton L, Hudis CA.
    Breast Cancer Res Treat; 2005 Mar 21; 90(2):157-63. PubMed ID: 15803362
    [Abstract] [Full Text] [Related]

  • 20. A phase II trial of imatinib mesylate in patients with metastatic pancreatic cancer.
    Gharibo M, Patrick-Miller L, Zheng L, Guensch L, Juvidian P, Poplin E.
    Pancreas; 2008 May 21; 36(4):341-5. PubMed ID: 18437079
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.